Alexis Vandier, Global Head of Servier Ventures, shared Servier’s post on LinkedIn, adding:
“A new chapter with the same mission: accelerating innovation to bring new solutions for patients.
After three incredible years dedicated to bringing a breakthrough innovation to patients fighting brain cancer – first innovation in 20 years, Galien prize winning award – I am transitioning to a new role within Servier.
I want to express my deepest gratitude to my former Asset cross-functional team. Your talent, your determination, and your commitment toward patients have allowed to make the impossible possible. It has been a privilege to serve this HCP and patients community alongside you. hashtag#willmissyou
Today, driven by that same ambition to deliver life-changing science, I am happy to announce my appointment as Global Head of Servier Ventures.
In this new role, I will lead Servier’s newly launched €200M corporate venture fund. Our mission is clear: to invest in the biotech and technological pioneers shaping the future of Oncology and Neurology. The focus is primarily Europe and late research/serie A rounds.
While my role is shifting toward the venture ecosystem, I will remain deeply connected to both the Onco and Neuro communities. And I will reconnect with the VC/Biotech world !
I look forward to supporting the next wave of ‘first-in-class’ and ‘best-in-class’ therapies that patients are waiting for. I’m heading to San Francisco for JPM26 this week—if you’re around, let’s connect!”
Quoting Servier’s post:
“We are pleased to announce the launch of Servier Ventures, our new strategic corporate venture fund, with an initial commitment of €200 million to invest in biotech and technology companies advancing breakthrough therapeutic approaches.
This initiative is a major step in accelerating access to innovation, with a primary focus on oncology and neurology across Europe.
As Alexis V., newly appointed Global Head of Servier Ventures, shared:
‘In line with the Group’s strategy, Servier Ventures will finance and support emerging biotech companies and, if needed, provide them access to Servier’s scientific expertise and capabilities, to boost their potential and foster the creation of innovative new medicines. The creation of the fund will strengthen Servier’s positioning as a partner of choice for promising companies seeking to take a strategic step forward, aligned with our focus toward innovation for the benefit of patients.’
Our mission remains clear: to drive therapeutic progress and address unmet patient needs by supporting transformative science for the benefit of patients worldwide.”
More posts about Servier.